[{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TD-1058","moa":"ALK5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Hammersmith Medicines Research | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"14-C GSK961081","moa":"Beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theravance Biopharma \/ Hammersmith Medicines Research | GSK","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Hammersmith Medicines Research | GSK"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Nephrology","graph2":"Phase IV","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"11","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Divestment","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Theravance Biopharma","amount2":1.55,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.55,"dosageForm":"Powder for Inhalation","sponsorNew":"Theravance Biopharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Theravance Biopharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2025","type":"Agreement","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Theravance Biopharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.23000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Theravance Biopharma \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Theravance Biopharma \/ GSK"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"TD-6450","moa":"HCV NS5A\/HCV NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"TD-6450","moa":"HCV NS5A\/HCV NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"Janus Kinase (JAK)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TD-8236","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TD-8236","moa":"Janus kinase 1 (JAK-1)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"TD-1211","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Nephrology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Theravance Biopharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Theravance Biopharma \/ Viatris"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Umeclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"11","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"TD-0714","moa":"Neutral endopeptidase (MME)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TD-0714","moa":"Neutral endopeptidase (MME)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"TD-8954","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theravance Biopharma \/ Theravance Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Theravance Biopharma \/ Theravance Biopharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"TD-8954","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Alfasigma","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Alfasigma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Alfasigma","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Alfasigma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TD-1439","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TD-1439","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"TD-1607","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"TD-1607","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TD-3504","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TD-5202","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Theravance Biopharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
